Acadia Pharmaceuticals Stock Performance
| ACAD Stock | USD 24.56 0.08 0.32% |
The firm owns a Beta (Systematic Risk) of 0.62, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ACADIA Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding ACADIA Pharmaceuticals is expected to be smaller as well. ACADIA Pharmaceuticals at this moment owns a risk of 2.12%. Please confirm ACADIA Pharmaceuticals mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to decide if ACADIA Pharmaceuticals will be following its current price history.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ACADIA Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, ACADIA Pharmaceuticals is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return (0.32) | Five Day Return 2.29 | Year To Date Return (6.58) | Ten Year Return 42.29 | All Time Return 266.57 |
1 | Stifel Maintains Hold Rating and Raises Price Target for ACAD to 25.00 ACAD Stock News - GuruFocus | 12/11/2025 |
2 | FTRE vs. ACAD Which Stock Is the Better Value Option | 01/12/2026 |
3 | Acadia Pharmaceuticals stock undervalued with 32 price target, says Canaccord - Investing.com Nigeria | 01/27/2026 |
4 | Guess which ASX 200 healthcare share is crashing 22 percent on Tuesday on European blow | 02/02/2026 |
5 | The Bull Case For ACADIA Pharmaceuticals Could Change Following EMA Setback For Trofinetide Approval | 02/03/2026 |
6 | Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 | 02/04/2026 |
7 | Disposition of 12944 shares by Rhodes Jennifer J of ACADIA Pharmaceuticals subject to Rule 16b-3 | 02/06/2026 |
8 | Disposition of 6950 shares by Rhodes Jennifer J of ACADIA Pharmaceuticals at 23.38 subject to Rule 16b-3 | 02/09/2026 |
9 | A Look At ACADIA Pharmaceuticals Valuation After Recent Share Price Weakness | 02/12/2026 |
10 | Oppenheimer Maintains A Balanced Outlook on ACADIA Pharmaceuticals Inc. For 2026 | 02/18/2026 |
11 | Acadia Pharma Q4 2025 Earnings Preview | 02/24/2026 |
| Begin Period Cash Flow | 194.4 M | |
| Total Cashflows From Investing Activities | -30.5 M |
ACADIA Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,485 in ACADIA Pharmaceuticals on November 30, 2025 and sell it today you would lose (29.00) from holding ACADIA Pharmaceuticals or give up 1.17% of portfolio value over 90 days. ACADIA Pharmaceuticals is currently generating 0.0027% in daily expected returns and assumes 2.1163% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than ACADIA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ACADIA Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of ACADIA Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 24.56 | 90 days | 24.56 | about 75.94 |
Based on a normal probability distribution, the odds of ACADIA Pharmaceuticals to move above the current price in 90 days from now is about 75.94 (This ACADIA Pharmaceuticals probability density function shows the probability of ACADIA Stock to fall within a particular range of prices over 90 days) .
ACADIA Pharmaceuticals Price Density |
| Price |
Predictive Modules for ACADIA Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ACADIA Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ACADIA Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ACADIA Pharmaceuticals is not an exception. The market had few large corrections towards the ACADIA Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ACADIA Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ACADIA Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.02 | |
β | Beta against Dow Jones | 0.62 | |
σ | Overall volatility | 1.59 | |
Ir | Information ratio | -0.0028 |
ACADIA Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ACADIA Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ACADIA Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ACADIA Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| ACADIA Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: Acadia Pharma Q4 2025 Earnings Preview |
ACADIA Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ACADIA Stock often depends not only on the future outlook of the current and potential ACADIA Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ACADIA Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 171.4 M | |
| Cash And Short Term Investments | 819.7 M |
ACADIA Pharmaceuticals Fundamentals Growth
ACADIA Stock prices reflect investors' perceptions of the future prospects and financial health of ACADIA Pharmaceuticals, and ACADIA Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ACADIA Stock performance.
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.0476 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 3.38 B | ||||
| Shares Outstanding | 169.18 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 4.54 X | ||||
| Price To Sales | 3.88 X | ||||
| Revenue | 1.07 B | ||||
| Gross Profit | 982.51 M | ||||
| EBITDA | 138.9 M | ||||
| Net Income | 226.45 M | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 40.55 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 7.25 X | ||||
| Cash Flow From Operations | 157.72 M | ||||
| Earnings Per Share | 1.55 X | ||||
| Market Capitalization | 4.16 B | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (2.2 B) | ||||
| Working Capital | 543.45 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
About ACADIA Pharmaceuticals Performance
By analyzing ACADIA Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into ACADIA Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ACADIA Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ACADIA Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 142.19 | 195.60 | |
| Return On Tangible Assets | 0.27 | 0.28 | |
| Return On Capital Employed | 0.08 | 0.09 | |
| Return On Assets | 0.25 | 0.26 | |
| Return On Equity | 0.32 | 0.33 |
Things to note about ACADIA Pharmaceuticals performance evaluation
Checking the ongoing alerts about ACADIA Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ACADIA Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ACADIA Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| ACADIA Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from seekingalpha.com: Acadia Pharma Q4 2025 Earnings Preview |
- Analyzing ACADIA Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ACADIA Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ACADIA Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ACADIA Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ACADIA Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ACADIA Pharmaceuticals' stock. These opinions can provide insight into ACADIA Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |